Professor Simon Hart's Projects (26)

1490-0004 - IPF Cohort Aug 1, 2024 - Nov 30, 2025

BI1819479 IN IPF / 1462-0004 Aug 1, 2024 - Jun 30, 2026

BEACON-IPF Jun 1, 2024 - Jul 31, 2025

ALOFT-PPF Jun 1, 2024 - Sep 30, 2027

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate theEfficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary fibrosis Nov 1, 2023 - Feb 28, 2027

Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Feb 1, 2024 - Jun 30, 2025

Fully humanised model of ageing endothelium to study ageing-associated lung diseases: Apr 1, 2024 - Jan 1, 2025

HEIF: Simplifying patient information for clinical trials Aug 1, 2023 - Jul 31, 2024
Clinical trials are the main mechanism for improving patient care. They are an important source of income for the University and HUTH. The output in terms of publications and impact generated contributes greatly to the REF submission.

In order to... Read More about HEIF: Simplifying patient information for clinical trials.

A multi-centre, real-world exploratory cohort study to evaluate cough frequency, severity, and impact on quality of life in patients with non-idiopathic pulmonary fibrosis interstitial lung disease. Dec 1, 2022 - Nov 30, 2023
ILD

BREEZE 2: A randomised controlled trial of a complex intervention to manage breathlessness in pulmonary fibrosis Apr 1, 2024 - Mar 31, 2026
Full trial based on BREEZE feasibility trial

Study of the lung endothelium in idiopathic pulmonary fibrosis Sep 1, 2020 - Sep 30, 2023

A cell model for discovering biomarkers and druggable targets for pulmonary fibrosis May 1, 2023 - Jan 31, 2025

Updating (Reviewing and Printing) the Patient's Guide to Pulmonary Fibrosis. Nov 1, 2022 - Oct 31, 2023
This is an annual follow up/annual review for the Project 3632727: Development And Publication Of The Booklet For The Pulmonary Fibrosis (disease With A Degree Of Similarity To Coronavirus Disease).


Chronic diseases associated with fibrosis pres... Read More about Updating (Reviewing and Printing) the Patient's Guide to Pulmonary Fibrosis..

COASPIRE: A randomised, double-blind, placebo controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2 Nov 1, 2021 - Oct 31, 2022

Development and publication of the booklet for the pulmonary fibrosis (disease with a degree of similarity to coronavirus disease). Nov 1, 2020 - Oct 31, 2021
Chronic diseases associated with fibrosis present a challenge for healthcare; two of them are idiopathic pulmonary fibrosis (IPF) and lymphoedema. IPF is a form of lung disease in which scarring occurs (with no known cause) leading to increased breat... Read More about Development and publication of the booklet for the pulmonary fibrosis (disease with a degree of similarity to coronavirus disease)..

An exploratory sub-study to protocol GLPG1690-CL-303 to assess lung function in patients with idiopathic pulmonary fibrosis, using hyperpolarized xenon magnetic resonance imaging Nov 1, 2019 - Apr 30, 2022

TR12: A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbuphine ER Tablets for the Treatment of Cough Oct 1, 2019 - Dec 31, 2022

ATLAS: A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis Jun 1, 2019 - Jan 31, 2022

SCENIC: Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) May 1, 2019 - Jan 31, 2022

ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebocontrolled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. Aug 1, 2019 - Dec 31, 2022

A single arm, open-label exploratory clinical trial of azithromycin in pulmonary sarcoidosis Mar 1, 2019 - Sep 30, 2020
Patients with sarcoidosis need treatment options that improve their disease without causing unacceptable side effects. Currently, steroids tablets are offered for severe sarcoidosis, but side effects can be dangerous and personally distressing, and s... Read More about A single arm, open-label exploratory clinical trial of azithromycin in pulmonary sarcoidosis.

BETTER-B: BETter TreatmEnts for Refractory Breathlessness Jan 1, 2019 - Dec 31, 2023

Development and application of a multi-scale computational model of sarcoidosis to predict therapeutic approaches for non-self-resolving disease Jun 30, 2017 - Aug 31, 2020
An in silico computational model of sarcoidosis

Sir Jules Thorn PhD Scholarship Programme 2016 Sep 1, 2016 - Aug 31, 2019
Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the lungs that affects about 15,000 people in the UK. There is no curative treatment and 5-year survival in IPF is worse than many cancers. Despite this, the pathogenesis of IPF... Read More about Sir Jules Thorn PhD Scholarship Programme 2016.

Characterisation of monocyte CD200R in pulmonary sarcoidosis Mar 1, 2016 - Feb 28, 2018

BREATHE: Breathlessness RElief AT HomE Apr 1, 2019 - Oct 31, 2021
A feasibility study to address this RQ:
Does a paramedic-administered short non-pharmacological complex breathlessness intervention improve breathlessness and reduce conveyance to ED for people with breathlessness crisis compared with usual practice... Read More about BREATHE: Breathlessness RElief AT HomE.